Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer
Authors:
- 1 February 2015
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 15 (1) , 60-65
Abstract
No abstract availableKeywords
Funding Information
- ARIAD Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Merck & Co., Inc.
This publication has 24 references indexed in Scilit:
- Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer ModelsMolecular Cancer Therapeutics, 2011
- Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing RegimensMolecular Cancer Therapeutics, 2011
- Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatmentsHistopathology, 2010
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- RETRACTED: Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt SignalingPLOS ONE, 2008
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Overexpression of ErbB2 in cancer and ErbB2-targeting strategiesOncogene, 2000